Spatial cytotoxic and memory T cells in tumor predict superior survival outcomes in patients with high-grade serous ovarian cancer

Guodong Zhang¹,² | Qing Xu¹,² | Xiangyun Zhang³ | Moran Yang¹,⁴ | Yiying Wang¹,⁴ | Mengdi He¹,² | Jiaqi Lu¹,⁵ | Haiou Liu¹,⁴ *

¹Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China
²Department of Obstetrics and Gynecology of Shanghai Medical School, Fudan University, Shanghai, China
³Department of Gynecology, Suzhou Municipal Hospital, Suzhou, China
⁴Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Shanghai, China
⁵Department of Gynecology, Kashgar Prefecture Second People’s Hospital, Kash, China

Abstract
Although the association between tumor-infiltrating CD3⁺ T and CD8⁺ T cells and superior survival in high-grade serous ovarian cancer (HGSOC) has been observed, the different spatial localization of tumor-infiltrating lymphocytes (TILs) possesses heterogeneous effects. We performed localized measurements in 260 HGSOC from 2 independent cohorts represented in tissue microarray format to determine the localized expression pattern and clinical significance of CD3⁺ T, CD8⁺ T, and CD45RO⁺ cells in HGSOC. Different density of spatial localization of CD3⁺ T, CD8⁺ T, and CD45RO⁺ cells exhibited heterogeneous association with OS. The combination of the center of the tumor and invasive margin localized CD8⁺ T cells (CD8 CT&IM) with the same margin localized CD45RO (CD45RO CT&IM) was the most robust prognostic predictor. Immune score (IS) was constructed by integrating FIGO stage with CD8 CT&IM and CD45RO IM&CT and had the best prognostic value in HGSOC. The low-, intermediate-, and high-IS groups were observed in 44.7%, 41.6%, and 13.7% of patients, respectively. Low-IS identified patients were at higher risk of death compared to high-IS identified patients (HR = 12.426; 95% CI 5.317–29.039, p < 0.001); meanwhile, we evaluate the RMSTs over 10 years of follow-up and obtained RMST values of 104.09 months (95% CI 96.31–111.87 months) in the high-IS group, 75.26 months (95% CI 59.92–90.60 months) in the intermediate-IS group, and 48.68 months (95% CI 38.82–58.54 months) in the low-IS group. In general, spatial localization can modulate the clinical effects of TILs in HGSOC. Thus, the spatial expression of CD8 and CD45RO could aid clinicians to determine the follow-up plan of patients with HGSOC.

KEYWORDS
cytotoxic T cells, high-grade serous ovarian cancer, memory T Cells, overall survival, prognostic model
INTRODUCTION

Epithelial ovarian tumor is the seventh most common female cancer and the overall 5-year survival rate is only 46%. The clinical manifestations of epithelial ovarian tumors are not obvious in the early stage, and about 75% of patients have entered the advanced stage at the time of diagnosis. High-grade serous cancer (HGSOC) has the highest incidence and mortality among different types of epithelial ovarian cancer. In recent years, the survival rate of patients with HGSOC has hardly been improved because of early detection, relapse, drug resistance, and other characteristics.

Previous studies have demonstrated that heterogeneity of immune cell infiltration in ovarian cancer which may influence the development, occurrence, and prognosis of ovarian cancer. T cells have been found to play an important role in the treatment of tumors, and CD3+, CD8+, and CD45RO+ T cells have been individually reported associated with favorable survival. Several studies have observed that the combination of CD8+ and CD45RO+ T cells was a better indicator of patient prognosis in colorectal cancer. In addition to the quantity, the location of immune cell infiltration has a different contribution to prognosis.

In this study, we confirmed that infiltrating intertumoral T cells were correlated with a decreased incidence of death. Then, the location of CD3+, CD8+, and CD45RO+ T cells was also correlated with overall survival and the combination of them has more significance. Additionally, a prognostic model of the T cells and clinical information was established and validated.

MATERIALS AND METHODS

Population

Training Cohort: A retrospective series of 190 formalin-fixed paraffin-embedded (FFPE) samples were obtained from patients with HGSOC who underwent primary surgery in the absence of neoadjuvant chemotherapy between March 2013 and November 2015 from Obstetrics and Gynecology Hospital of Fudan University. All samples were taken from primary lesions. Pathology staging was performed according to the FIGO (International Federation of Gynecology and Obstetrics) classification (2018), and histologic types were determined according to the current WHO classification. Data on clinical outcomes were obtained retrospectively by interrogation of families and the last follow-up is September 2019. Validation Cohort: A retrospective series of 70 formalin-fixed paraffin-embedded samples from patients of HGSOC was collected between May 2013 and August 2018 at Suzhou Municipal Hospital who underwent primary surgery in the absence of neoadjuvant chemotherapy. All samples were taken from primary lesions. Data on clinical outcomes were obtained retrospectively by interrogation of families and the last follow-up is March 2019. The clinicopathological characteristics of the training and validation cohort were both shown in Table S1. There was no difference of all clinicopathologic characteristics between the two cohorts but ascites. Perhaps it is because the limited patients and different areas. All participants included in this study provided written informed consent, which allowed us to use their specimens and data for publication. The objective assessment of progressive disease was determined by central radiologic and clinical review in a blinded manner, according to RECIST (Response Evaluation Criteria in Solid Tumors), version 1.1.

Patients were divided to the low CA125 concentration group with a concentration equal to or below 35 U/ml, while the high CA125 concentration group possessed concentrations higher than 35 U/ml. The LN metastasis was defined the patients with clinical and pathological diagnosis of LN metastasis except patients unreceived cytoreductive surgery which did not need pathological diagnosis.

Tissue microarray construction and immunohistochemistry

Hematoxylin and eosin (H&E)–stained slides of tissues were reviewed without knowledge of clinical characteristics or outcomes. Each section H&E-stained slide was evaluated for the presence of the center of the tumor (CT), the invasive margin (IM), and interstitium (IN) (Figure 1A-E). For each tumor specimen, two 4-μm cores containing regions of CT, IM, and IN were selected from the areas containing the highest density of immune cells to make tissue microarray. Immunohistochemistry (IHC) was performed through deparaffinizing, rehydrating, antigen retrieval, blocking, incubating primary and secondary antibody, visualizing with applicable antibodies CD45RO (OPD4), CD8 (4B11), and CD3 (SP7).

To assess the density of stained immune cells, three representative areas were screened under a 200x microscope vision by two separate pathologists blinded to patient clinicopathological data and clinical results. IHC staining cells in each region were quantified and counted as the number of cells in each region. The two pathologists independently scored the microarrays and paired the score at the end. The microarrays were scored independently by two pathologists who matched scores at the end. The average of their evaluations was used to count. The count of variation, more than 3 cells, was reassessed by two pathologists to gain consensus. The coefficients
of variation between two different cores and two separate pathologists were both <15%. Meanwhile, an algorithm developed for the NIH software ImageJ was also used to make sure the repeatability of results. The range for IHC score was from 0 to 38. The cut-off value for basophils high/low subgroups was determined by X-tile software (X-tile Version 3.6.1, Yale University, CT, USA, https://xtile.software.informer.com/). The number 0 was selected as the cut-off and the cohort was divided into immune cell negative (neg) and positive (pos) groups. In addition, we divided the cohort into double positive (DP), single positive (SP) and negative groups when two kind of immune cells used.

2.3 Statistical analysis

Kaplan–Meier curves and Cox proportional hazards regression were performed by Medcalc software (version 18) and their significance was assessed by the log-rank test. The receiver operating characteristic (ROC) curves, area under curve (AUC), Akaike information criterion (AIC), index of concordance (C-index), and the restricted mean survival time (RMST) were performed R software packages (version 3.5.1). A chi-square test was used to examine the significance between different immune cell infiltration groups and clinical information by Medcalc software (version 18).

3 RESULTS

3.1 Density and location of T Cells associated with prognosis in HGSOC

In order to study the infiltration of T cells, we investigated the densities of CD3+, CD8+, and CD45RO+ T cells infiltration in the mass (All) and regions (CT, IM, and IN) which staining brown by IHC and found T cells differently infiltrated in distinct areas (Figure 1F). Moreover, we set a density of 0 as their cut-offs to divide all patients to positive (Pos) group and negative (Neg) group.

We used Kaplan–Meier analysis to evaluate the relationship between CD3+, CD8+, and CD45RO+ T cells in all regions, and prognosis in the training cohort. The appearance of T cells was significantly correlated with favorable overall survival (OS) in mass and the three regions except for CD3+, CD8+ T cells in IN (Figure 2A-C, CD3, $p = 0.002$ HR = 2.045; CD8, $p = 0.002$, HR = 2.073; CD45RO, $p < 0.001$, HR = 3.012, Figure S1A-I, all $p < 0.001$ except

![Figure 1](https://zhangetal.com/f1.png)
To improve efficiency, we incorporated T cells in regions that have significant correlations with OS (CD3_{CT&IM}, CD8_{CT&IM}, CD45RO_{CT&IM}, and CD45RO_{CT&IM&IN}). These curves showed infiltrating T cells in all regions associated with improved OS and strongly discriminate different prognosis with superior hazard risk between two groups (Figure 2D-F, Figure S1J, all \( p < 0.001 \)).

Hazard ratio (HR), C-index, AUC, and AIC analyses were performed to compare the efficiency of T cells in mass and regions and found these indexes of T cells combined with CT and IM were superior to than in mass and the three regions except for AUC of CD3_{CT&IM} (Table 1). Comparing with CD45RO_{CT&IM&IN}, CD45RO_{CT&IM} had higher HR, C-index, AUC, and lower AIC. Therefore, we would use CD3_{CT&IM},
CD8CT&IM, and CD45ROCT&IM as separate indicators in the following studies.

### 3.2 Integrated evaluation of cytotoxic and memory T cells in quality and space well predicted overall survival

We further investigated the combined forms of the three combined markers to search for the optimal results. First, we combined two of the three and all the three combined markers to identify patients with both positive markers as double positive (DP) group, patients with both negative as Neg group, and the others as single positive (SP) group based on the previous results. The survival curves manifested the patients in the DP groups of CD3&CD8, CD3&CD45RO, CD8&CD45RO, and CD3&CD8&CD45RO had the best prognosis, while the SP and Neg groups had the opposite (Figure 3A-D, all p < 0.001). RMST was used to identify the prognostic significance of the SP group compared with DP and Neg groups with choosing the longest time as the end (Table 2). With the application of C-index, AIC, RUC curves, and AUC, we detect that the integration of CD8CT&IM and CD45ROCT&IM had the strongest prediction effect than any single or integrated marker (Table 2, Figure 3E).

The correlation of clinicopathological characteristics with CD8&CD45RO was summarized in Table S2. In addition, we found the distribution of FIGO stage in CD8&CD45RO groups was extraordinarily unequal the Neg group had the most patients with late-stage (Figure 3F). Moreover, a statistically significant interaction was observed for the predictive value of IS in term of progress free survival (PFS, p < 0.001).

### 3.3 Construction of the prognostic model incorporating immune infiltrates and clinical characteristic

In the training cohort, the univariate COX regression analysis suggested that age, ascites, residual, lymph nodes (LN) metastasis, therapy response, FIGO stage, and CD8&CD45RO were statistically or nearly significant with overall survival and above all were analyzed by multivariate COX regression. The result of the multivariate COX regression indicated...
**Training Cohort**

(A) Overall Survival

- CD3&CD8
  - Group: DP
  - Group: SP
  - Group: Neg

(B) Overall Survival

- CD3&CD45RO
  - Group: DP
  - Group: SP
  - Group: Neg

(C) Overall Survival

- CD8&CD45RO
  - Group: DP
  - Group: SP
  - Group: Neg

(D) Overall Survival

- CD3&CD8&CD45RO
  - Group: DP
  - Group: SP
  - Group: Neg

(E) ROC curves

- CD8&CD45RO: AUC=0.823
- CD3&CD45RO: AUC=0.794
- CD3&CD8: AUC=0.623
- CD3&CD8&CD45RO: AUC=0.81

(F) Percentage

- CD8&CD45RO
  - DP: 66.7%
  - SP: 81.6%
  - Neg: 83.9%

(G) Progress Free Survival

- CD8&CD45RO
  - Group: DP
  - Group: SP
  - Group: Neg

**p<0.0001**
FIGO stage, and CD8&CD45RO were obviously associated with overall survival after backward stepwise selection (Figure 4A, Table S3). A prediction model named immunoscore (IS) was developed by incorporating FIGO stage and CD8&CD45RO to provide a quantitative tool for evaluating the survival probability rely on risk proportional regression. We set up FIGO stage I+II and CD8&CD45RO Neg as baseline, then the coefficients of the two variables were used to represent FIGO stage III+IV, CD8&CD45RO DP and SP. Finally, the sum of the value of FIGO stage and CD8&CD45RO was IS, and based this result, the IS was divided to three groups by X-tile. The Kaplan–Meier curve and RMST indicated IS could stratify patients with HGSOC to three groups with different prognosis (Figure 4B, Table 2). Importantly, this model has the most remarkable effectiveness than the indicator of CD8&CD45RO and FIGO stage by comparison of ROC, C-index, AUC, and AIC (Figure 4C, Table 3). IS was also observed significantly associated with PFS but the efficiency of CD8&CD45RO and IS were both weaker than FIGO (Figure 4D, Table 3).

CD8&CD45RO was further verified by Kaplan–Meier in the validation cohort which showed the same statistical significance as the training cohort (Figure 5A). Moreover, we also calculated IS and performed its Kaplan–Meier curve (Figure 5B). It can be confirmed that the model is superior to CD8 & CD45RO and FIGO stage in prediction efficiency by calculating ROC, C-index, AUC, and AIC (Figure 5C, Table 4). There were some differences between the results of the two cohorts which may be due to the limited amount of the validation cohort.

### DISCUSSION

Efficient assessment of patients’ risk after the surgery is crucial for the therapy of HGSOC. In this study, the heterogeneity of immune infiltrates was observed in HGSOC based on CD3+ T cells, CD8+ cytotoxic T cells, and CD45RO+ memory T cells. We had evaluated the predictive effect of CD3+, CD8+, and CD45RO+ T cells in CT, IM, and IN regions and various kinds of combinations in the training cohort. The combinations of T cells infiltration in regions had more powerful predictive efficiency than those in mass. Furthermore, we got a prominent integrated indicator, CD8&CD45RO which could divide patients with epithelial ovarian cancer to three groups of different risk through different combinations and verification. Lastly, a quantitative tool was constructed to evaluate the survival probability depend on clinical characteristics and CD8&CD45RO which had been verified in the validation cohort.

Comparing with the other joint indicators, CD8&CD45RO appeared the most efficient in predicting survival outcomes after surgery which could be applied in patients with different...
FIGURE 4  The IS consists of clinical characteristics and CD8&CD45RO in the training cohort. (A) The univariate and multivariate COX regression of clinical characteristics and CD8&CD45RO in term of OS. (B) The Kaplan–Meier curve of IS. (C) ROC curves of CD8&CD45RO, FIGO stage, and IS. (D) Kaplan-Meier curve of IS in term of PFS.
|                   | Log-rank     | RMST                  |
|-------------------|--------------|-----------------------|
|                   | p-value⁴     | HR        | 95% CI | Value (months) | p-value⁴ | C-index | AUC  | AIC |
| OS                | CD8&CD45RO   | <0.0001   | 9.964  | 4.653–21.338 | DP (102.849, 93.751–111.963) vs. SP (75.262, 59.920–90.603) | <0.0001 | 0.716  | 0.823 | 715.683 |
|                   |              | Neg vs. DP | 4.230  | 2.689–6.653  | SP (75.262, 59.920–90.603) vs. Neg (48.678, 38.824–58.536) | 0.004   |
|                   |              | Neg vs. SP | 4.230  | 2.689–6.653  | DP (102.849, 93.751–111.963) vs. Neg (48.678, 38.824–58.536) | <0.0001 |
| IS                | Lo vs. Hi    | 12.426    | 5.317–29.039 | Hi (104.091, 96.312–111.872) vs. Int (82.658, 68.065–97.242) | 0.002   | 0.753  | 0.854 | 707.294 |
|                   |              | Lo vs. Int | 5.167  | 3.259–8.193  | Int (82.658, 68.065–97.242) vs. Lo (55.080, 44.680–65.477) | 0.003   |
|                   |              |            |        |              | Hi (104.091, 96.312–111.872) vs. Lo (55.080, 44.680–65.477) | <0.0001 |
| FIGO stage        | \            | \         | \      | \            | \        | 0.647  | 0.749 | 734.014 |
| PFS               | CD8&CD45RO   | <0.0001   | 4.152  | 1.804–9.554  | DP (92.793, 82.212–103.356) vs. SP (81.741, 70.749–92.740) | 0.156   | 0.554  | 0.562 | 660.364 |
|                   |              | Neg vs. DP | 1.547  | 0.932–2.560  | SP (46.560, 41.450–51.671) vs. Neg (29.808, 19.973–39.651) | 0.003   |
|                   |              | Neg vs. SP | 1.547  | 0.932–2.560  | DP (53.986, 49.751–58.212) vs. Neg (29.808, 19.973–39.651) | <0.0001 |
| IS                | Lo vs. Hi    | 5.271     | 2.087–13.308 | Hi (95.977, 86.661–105.305) vs. Int (74.382, 62.300–86.463) | 0.006   | 0.507  | 0.504 | 664.346 |
|                   |              | Lo vs. Int | 2.217  | 1.338–3.674  | Int (42.575, 37.085–48.080) vs. Lo (28.571, 17.713–39.420) | 0.024   |
|                   |              |            |        |              | Hi (54.490, 50.948–58.034) vs. Lo (28.571, 17.713–39.420) | <0.0001 |
| FIGO stage        | \            | \         | \      | \            | \        | 0.614  | 0.619 | 651.603 |

Abbreviations: AIC, Akaike information criterion; AUC, Area under curve; CI, Confidence interval; FIGO, The International Federation of Gynecology and Obstetrics; HR, Hazard risk; IS, Immune score; RMST, Restricted mean time lost.

⁴p-value <0.05 marked in bold font shows statistical significance.
pathological diagnoses. According to our findings, patients can be stratified into three prognostic categories with significantly different overall survival. The Hi group had a prolonged OS differed from that of patients in the Lo group, as well as favorable clinical characteristics. Multivariate COX analysis, combining age, ascites, residual, lymph nodes (LN) metastasis, therapy response, FIGO stage, and CD8&CD45RO, supports the advantage of CD8&CD45RO over HGSOC in predicting survival which indicated the possibility of application in clinical practice. Besides, the IS comprising FIGO stage and LVSI exhibited more robust performance in predicting OS probability instead of PFS. These observations possessed relatively high credibility and applicability on account of clinical samples. Unfortunately, the size of the population was limited, and our research lacked the exploration of mechanisms.

In general, the tumor-infiltrating T cells play important roles in epithelial ovarian cancer, including cytotoxic T cells, memory T cells, regulatory T cells, and so on. In our research, we focused on cytotoxic T cells and memory T cells which have not been jointly reported in HGSOC. CD3⁺, CD8⁺, CD45RO⁺ cells represent T cells, cytotoxic T cells, and memory T cells. Although CD3⁺ was not included in final model, the infiltration of CD3⁺ T cells in tumor was obviously associated with prognosis. CD8⁺ cytotoxic and CD45RO⁺ memory T cells play vital roles in antitumor immune responses and could supply more new therapeutic targets. It has been confirmed that high levels of tumor-infiltrating cytotoxic T cells and memory T cells associated with favorable survival and clinical characteristics in many human cancers which suggested a protective role of immune infiltrates of T cells in previous studies. Previous clinical
| Evaluation indexes of different combination of CD3, CD8, and CD45RO in validation cohort |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                                | Log-rank p-value | HR               | 95% CI          | RMST Value (months) | p-value AIC   |
| CD8&CD45RO                     | <0.0001          |                  |                 |                  |                |
|                                |                 | Neg vs. DP       | 16.805          | 4.55–62.062       | 0.358          |
|                                |                 | Neg vs. SP       | 3.113           | 0.795–12.179      | <0.0001        |
| IS                             | <0.0001          |                  |                 |                  |                |
|                                |                 | Lo vs. Hi        | 23.055          | 4.495–118.2547    | 0.020          |
|                                |                 | Lo vs. Int       | 7.189           | 2.001–25.822      | 0.017          |
| FIGO stage                     | \               | \               | \              | \               | \              |
|                                | Hi (52.69, 50.14–55.24) vs. Lo (23.60,13.01–34.19) | <0.0001          |                  |                |

**Abbreviations:** AIC, Akaike information criterion; AUC, Area under curve; CI, Confidence interval; FIGO, The International Federation of Gynecology and Obstetrics; HR, Hazard risk; IS, Immune score; RMST, Restricted mean time lost.

* p-value <0.05 marked in bold font shows statistical significance.
trials with immune checkpoint inhibitors have failed in terms of clinical outcome for ovarian cancer which suggested the multiple immune models and mechanisms. In our research, Cytotoxic CD8+ T cell in memory phase may have important function in ovarian cancer TME which could supply new a new approach for the study of immune therapy. A variable description of subjective ratings and incomplete combinations favors the previously found insufficient reliability.13,17 Our explorations examined all combinations of the immune infiltrates’ density and the location of immune cell populations in distinct tumor territories. We will explore other T cells such as CD4 T cell, type 1 T cell, regulatory T cell and so on in next study on tumor-infiltrating T cells in HGSOC.

HR of log-rank in Kaplan–Meier analysis can only indicate the risk of death which is not a probability measure and the p-value can not prove the significance between the intermediate group and the other groups associated with OS.41,42 When using HR, it is necessary to assume proportional hazards (PH), that is, HR will not change with time, and the failure of proportional hazards assumption will often occur during the long follow-up.41,42 Without a reference value for hazard in the low group, it is not easy for clinical practitioners and patients to understand the implications of HR values.43 Therefore, we used RMST as a quantitative measure to solve the problems above. For IS in the training cohort, we evaluate the RMSTs over 120 months of follow-up and obtained RMST values of 104.09 months in the high group, 67.92 months in the intermediate group, and 41.67 months in the low group. The RMST difference is 36.17 months (p < 0.001) between patients in high group and those in intermediate group, 26.25 months (p < 0.001) between patients in intermediate group and those in low group, and 62.41 months (p < 0.001) between patients in the high group and in the low group. RMST supplied a clinically meaningful summary measure of survival time for each group.40,41 Moreover, C-index and AUC were performed to evaluate the prediction efficiency of all markers for survival time and AIC was also used to measure the goodness of statistical model fitting.44 IS was the most efficient and robust prognostic marker for patients with HGSOC based multiple indexes mentioned.

In summary, our investigations supply powerful evidence for the usefulness of the combined evaluation of cytotoxic and memory T cells for the prediction of survival in patients with epithelial cancer. To be incorporated into clinical practice, we developed a new predictive model that included clinical features and immune infiltrates to enhance the credible impact on the outcome.

ACKNOWLEDGMENTS
This study was funded by grants from National Key Research and Development Program of China (2016YFC1303100), National Natural Science Foundation of China (82072881, 31570803 81773090), Natural Science Foundation of Shanghai (20ZR1409000), and FDUROP (Fudan’s Undergraduate Research Opportunities Program) (19052).

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ETHICAL APPROVAL AND ETHICAL STANDARDS
This study was conducted following the Declaration of Helsinki and was approved by the Ethics Committee of Obstetrics & Gynecology Hospital, Fudan University (Ky2016-49, for training cohort) and the Ethics Committee of Suzhou Municipal Hospital (2008–7–15, for validation cohort).

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Haiou Liu https://orcid.org/0000-0003-0200-8981

REFERENCE
1. Lheureux S, Gourley C, Vergote I, et al. Epithelial ovarian cancer. Lancet. 2019;393(10177):1240-1253. https://doi.org/10.1016/S0140-6736(18)32552-2.
2. Doherty JA, Peres LC, Wang C, et al. Challenges and opportunities in studying the epidemiology of ovarian cancer subtypes. Curr Epidemiol Rep. 2017;4(3):211-220. https://doi.org/10.1007/s40471-017-0115-y.
3. Singh N, McCluggage WG, Gilks CB. High-grade serous carcinoma of tubo-ovarian origin: recent developments. Histopathology. 2017;71(3):339-356. https://doi.org/10.1111/his.13248.
4. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492.
5. Hwang WT, Adams SF, Tahirovic E, et al. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis. Gynecol Oncol. 2012;124(2):192-198. https://doi.org/10.1016/j.ygyno.2011.09.039.
6. Zhang Z, Huang J, Zhang C, et al. Infiltration of dendritic cells and T lymphocytes predicts favorable outcome in epithelial ovarian cancer. Cancer Gene Ther. 2015;22(4):198-206. https://doi.org/10.1038/cgt.2015.7.
7. Raspolini MR, Castiglione F, Rossi Degg’innocenti D, et al. Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Ann Oncol. 2005;16(4):590-596. https://doi.org/10.1093/annonc/mdi112.
8. Jimenez-Sanchez A, Memon D, Pourpe S, et al. Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient. Cell. 2017;170(5):927-938.e20. https://doi.org/10.1016/j.cell.2017.07.025.
9. Preston CC, Goode EL, Hartmann LC, et al. Immunity and immune suppression in human ovarian cancer. ImmunoTherapy. 2011;3(4):539-556. https://doi.org/10.2217/imt.11.20.
10. Bachmayr-Heyda A, Aust S, Heinze G, et al. Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients—a study of the OVCAD consortium. *BMC Cancer*. 2013;13:422. https://doi.org/10.1186/1471-2407-13-422.

11. Keren L, Bosse M, Marquez D, et al. A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging. *Cell*. 2018;174(6):1373-1387.e19. https://doi.org/10.1016/j.cell.2018.08.039.

12. Nabe S, Yamada T, Suzuki J, et al. Reinforce the antitumor activity of CD8(+) T cells via glutamine restriction. *Cancer Sci*. 2009(12):3737-3750. https://doi.org/10.1111/j.1349-7006.2009.tb09335.x.

13. Pages F, Kirilovsky A, Mlecnik B, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. *J Clin Oncol*. 2009;27(35):5944-5951. https://doi.org/10.1200/JCO.2008.19.6147.

14. Sidaway P. Immunoscore provides a more accurate prognosis. *Nature Reviews Clinical Oncology*. 2018;15(8):471. https://doi.org/10.1038/s41571-018-0050-y.

15. Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. *J Pathol*. 2014;232(2):199-209. https://doi.org/10.1002/path.4287.

16. Pages F, Mlecnik B, Marliot F, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. *Lancet*. 2018;391(10135):2128-2139. https://doi.org/10.1016/S0140-6736(18)30789-X.

17. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. *Proc Natl Acad Sci*. 2005;102(51):18538-18543. https://doi.org/10.1073/pnas.0509182102.

18. Leffers N, Gooden MJ, de Jong RA, et al. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. *Cancer Immunol Immunother*. 2009;58(3):449-459. https://doi.org/10.1007/s00262-008-0583-5.

19. Feldmeyer L, Hugens CW, Ray-Lyons G, et al. Density, distribution, and composition of immune infiltrates correlate with survival in Merkel cell carcinoma. *Clin Cancer Res*. 2016;22(22):5553-5563. https://doi.org/10.1158/1078-0432.CCR-15-0392.

20. Javadi S, Ganeshan DM, Qayyum A, et al. Ovarian cancer, the revised FIGO staging system, and the role of imaging. *AJR Am J Roentgenol*. 2016;206(5):1351-1360.

21. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). *Eur J Cancer*. 2009;45(2):228-247.

22. Zhang H, Huo Q, Huang L, et al. Neutrophil-to-lymphocyte ratio in ovarian cancer patients with low CA125 concentration. *BioMed Res Int*. 2019;2019:8107906. https://doi.org/10.1155/2019/8107906.

23. Harter P, Heitz F, Ataseven B, et al. How to manage lymph nodes in ovarian cancer. *Cancer*. 2019;125(Suppl 24):4573-4577. https://doi.org/10.1002/cncr.32514.

24. Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. *CA Cancer J Clin*. 2018;68(4):284-296. https://doi.org/10.3322/caac.21456.

25. Prat J. Pathology of cancers of the female genital tract. *Int J Gynaecol Obstet*. 2015;12:S132-S145. https://doi.org/10.1016/j.ijgo.2015.06.010.

26. Wang W, Zou W, Liu JR. Tumor-infiltrating T cells in epithelial ovarian cancer: predictors of prognosis and biological basis of immunotherapy. *Gynecol Oncol*. 2018;151:1-3. https://doi.org/10.1016/j.ygyno.2018.09.005.

27. Reiser J, Effector BA, Memory, and dysfunctional CD8(+) T cell fates in the antitumor immune response. *J Immunol Res*. 2016;8941260: https://doi.org/10.1155/2016/8941260.

28. Fu C, Jiang A. Dendritic cells and CD8 T cell immunity in tumor microenvironment. *Front Immunol*. 2018;9: https://doi.org/10.3389/fimmu.2018.00309.

29. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. *Nat Immunol*. 2013;14(10):1014-1022. https://doi.org/10.1038/ni.2703.

30. Durgeau A, Virk Y, Corgnac S, et al. Recent advances in targeting CD8 T-cell immunity for more effective cancer immunotherapy. *Front Immunol*. 2018;9: https://doi.org/10.3389/fimmu.2018.00014.

31. Leclerc M, Voisin E, Gros G, et al. Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1. *Nat Commun*. 2019;10(1): https://doi.org/10.1038/s41467-019-11280-z.

32. Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. *Nat Med*. 2018;24(10):1550-1558. https://doi.org/10.1038/s41590-018-0136-1.

33. Mami-Chouaib F, Blanc C, Corgnac S, et al. Resident memory T cells, critical components in tumor immunology. *J Immunother Cancer*. 2018;6(1): https://doi.org/10.1186/s40428-018-0399-6.

34. Goode EL, Block MS, Kalli KR, et al. Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. *JAMA Oncol*. 2017;3(12):e173290. https://doi.org/10.1001/jamaoncol.2017.3290.

35. Glare MA, Domingo E, Sveen A, et al. Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage. *Br J Cancer*. 2019;121(6):474-482. https://doi.org/10.1038/s41461-019-0540-4.

36. Lee HE, Chae SW, Lee YJ, et al. Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. *Br J Cancer*. 2008;99(10):1704-1711. https://doi.org/10.1038/sj.bjc.6604738.

37. Paulsen EE, Kilvaer T, Khanhkenari MR, et al. CD45RO+ Memory T Lymphocytes — a candidate marker for TNM-immunoscoring in squamous non–small cell lung cancer. *Neoplasia*. 2015;17(11):839-848. https://doi.org/10.1016/j.neo.2015.11.004.

38. Donnem T, Hald SM, Paulsen EE, et al. Stromal CD8+ T-cell density—a promising supplement to TNM staging in non-small cell lung cancer. *Clin Cancer Res*. 21(11):2653-2643. https://doi.org/10.1158/1078-0432.CCR-14-1905.

39. Hu G, Wang S. Tumor-infiltrating CD45RO+ memory T lymphocytes predict favorable clinical outcome in solid tumors. *Sci Rep*. 2017;7(1): https://doi.org/10.1038/s41598-017-11122-2.

40. Egelston CA, Avalos C, Tu TY, et al. Resident memory CD8+ T cells within cancer islands mediate survival in breast cancer patients. *JCI Insight*. 2019;4(19): https://doi.org/10.1172/jci.insight ht.130000.

41. Alexander BM, Schoenfeld JD, Trippa L. Hazards of hazard ratios—deviations from model assumptions in immunotherapy. *N Engl J Med*. 2018;378(12):1158-1159. https://doi.org/10.1056/NEJMct1716612.

42. Uno H, Claggett B, Tian L, et al. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. *J Clin Oncol*. 2014;32(22):2380-2385. https://doi.org/10.1200/JCO.2014.55.2208.
43. Pak K, Uno H, Kim DH, et al. Interpretability of cancer clinical trial results using restricted mean survival time as an alternative to the hazard ratio. *JAMA*. 2017;3(12):1692-1696. https://doi.org/10.1001/jamaoncol.2017.2797.

44. A’Hern RP. Restricted mean survival time: an obligatory end point for time-to-event analysis in cancer trials? *J Clin Oncol*. 2016;34(28):3474-3476.

**SUPPORTING INFORMATION**
Additional supporting information may be found online in the Supporting Information section.